Howard Lightfoot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Howard Lightfoot has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Mathew J. Garnett
Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
158 shared publications - Syd Barthorpe
Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom
154 shared publications - Annie Wai Yeeng Chai
Translational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia
87 shared publications - Pei San Yee
Translational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia
87 shared publications - Shi Mun Yee
Translational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia
87 shared publications - Sok Ching Cheong
Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
87 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contain information on the Cell lines and organoids used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contain information on the Cell lines and organoids used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contains details of the BE sgRNA library
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contains details of the BE sgRNA library
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Supplementary Figure 1. Generating base editor-expressing MSI cell lines for screening. Supplementary Figure 2. Quality control for base-editor screens in MSI cell lines. Supplementary Figure 3. Discovery and characterization of novel inhibitors of WRN helicase. Supplementary Figure 4. Correlation of WRN inhibitor sensitivity with genetic and molecular markers in MSI models. Supplementary Figure 5. Comparative analysis of DNA damage in MSI and MSS cells treated with WRN inhibitors and genetic inactivation. Supplementary Figure 6: Effects of GSK_WRN4 on MSI and MSS colorectal cancer xenografts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Supplementary Figure 1. Generating base editor-expressing MSI cell lines for screening. Supplementary Figure 2. Quality control for base-editor screens in MSI cell lines. Supplementary Figure 3. Discovery and characterization of novel inhibitors of WRN helicase. Supplementary Figure 4. Correlation of WRN inhibitor sensitivity with genetic and molecular markers in MSI models. Supplementary Figure 5. Comparative analysis of DNA damage in MSI and MSS cells treated with WRN inhibitors and genetic inactivation. Supplementary Figure 6: Effects of GSK_WRN4 on MSI and MSS colorectal cancer xenografts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This table lists the results from Base editing screen
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This table lists the results from Base editing screen
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
List of 142 significant positively correlated drug-gene pairs
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
List of 142 significant positively correlated drug-gene pairs
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Necroptosis is activated in the absent of CASP8 upon AZD5582 treatment as shown by induction of p-MLKL.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Necroptosis is activated in the absent of CASP8 upon AZD5582 treatment as shown by induction of p-MLKL.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Ln IC50 data of 339 compounds in 21 OSCC cell lines
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Ln IC50 data of 339 compounds in 21 OSCC cell lines
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
All uncropped western blot images
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
All uncropped western blot images
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
A subset of OSCCs is vulnerable to AZD5582 and other IAP inhibitors.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
A subset of OSCCs is vulnerable to AZD5582 and other IAP inhibitors.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Supplementary Table 3 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Supplementary Table 3 from High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis